All In Biotech

Drug Trial Radar · NCT07563010

Menin-Inhibitor Targeted Maintenance in AML

Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jun 2031

Study completion Jun 2031

Sponsor

Sponsor type
Research network
Collaborators
National Marrow Donor Program; Dana-Farber Cancer Institute
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.

Conditions

  • Relapsed Adult AML
  • Stem Cell Transplant Complications
  • Acute Myeloid Leukemia
  • Transplant-Related Hematologic Malignancy

Interventions

  • RevumenibDrug

    oral tablets

  • PlaceboDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse free survival (RFS) in KMT2Ar, NPM1m, and NUP98r AML in the Intent-to-Treat (ITT) population with a minimum of 1 year of follow-up post-randomization.Time frame: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.